H1 Raises $40M from CVS Health Ventures, Demonstrating Resilience of Data-Focused SaaS

H1, a nine-year-old healthcare data platform, has secured $40 million in funding led by CVS Health Ventures, the corporate venture capital arm of CVS/Aetna. The round underscores a broader shift in investor sentiment, with data-centric software companies proving more resilient than traditional workflow-based SaaS platforms in a challenging capital environment dominated by AI investments.

H1's business model centers on providing detailed information about physicians to pharmaceutical companies, hospital systems, and health insurers globally. CEO and co-founder Ariel Katz argues that data providers like H1 occupy a defensible position against AI disruption, contrasting them with workflow automation SaaS companies that could be vulnerable to replacement by AI models. Katz expressed confidence that AI models like Anthropic's Claude would not replicate H1's core function, and suggested that major AI companies may instead become customers seeking access to H1's physician data.

The startup did not actively seek this capital raise. H1 achieved cash flow and EBITDA profitability in the previous year and is forecasting growth exceeding 40% for the current year. However, the opportunity to partner with one of the world's largest healthcare companies proved compelling enough to pursue the investment. The company was last valued at $750 million when it raised $100 million in November 2021 at the height of the COVID-era tech bubble, led by Altimeter Capital.

Like many companies that raised capital before the 2022 valuation correction, H1 has prioritized achieving profitability while pursuing strategic acquisitions of smaller competitors and complementary businesses. The funding round highlights investor recognition that while many pre-AI era SaaS startups face headwinds, those with defensible data assets and proven business fundamentals continue to attract capital from both strategic corporate investors and traditional venture firms.